Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer

NCT01283204 | Completed Phase 2

• 1 other identifier: 4-2009-0596
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to evaluate the antitumor activity (i.e. progression free survival, overall survival, response rate, etc), safety and quality of life in patient with recurrent or metastatic gastric cancer during 4-regimen (i.e. SP, FL/Tax, FL/Doc, FOLFOX) based chemotherapy. In addition, it is to evaluate efficacy and adverse events of anticancer agents according to the results of pharmacogenetic study.

Conditions

Recurrent or Metastatic Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• progression free survival(PFS)

  Imaging assessments will be performed every 6 weeks until radiographically documented PD(Progressive Disease).

  6 weeks

Study Arms (4)

SP(S-1 with cisplatin)

ACTIVE COMPARATOR

SP \<Every 3 weeks\> 1. Day 1\~14 : TS-1 80mg/m2/day (PO) 2. Day 1 : CDDP 60mg/m2/day IVF 2hours 3. Day 15\~21 : Rest

Drug: SP

FL/Tax(Paclitaxel with Leucovorin with 5-FU)

ACTIVE COMPARATOR

FL/Tax \<Every q 3 weeks\> 1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours 2. Day1 : Leucovorin 20mg/m2 IVF for 1hour 3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Drug: FL/Tax

FL/Doc(Decetaxel with Leucovorin with 5-FU)

ACTIVE COMPARATOR

FL/Doc \<Every q 3 weeks\> 1. Day1 : Docetaxel 75mg/m2 IVF for 1hour 2. Day1 : Leucovorin 20mg/m2 IVF for 1hour 3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Drug: FL/Doc

FOLFOX(Oxaliplatin with Leucovorin with 5-FU)

ACTIVE COMPARATOR

FOLFOX \<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours

Drug: FOLFOX

Interventions

SP DRUG

\<Every 3 weeks\> 1. Day 1\~14 : TS-1 80mg/m2/day (PO), 2. Day 1 : CDDP 60mg/m2/day IVF 2hours, 3. Day 15\~21 : Rest.

Also known as: TS-1® with Cisplatin

SP(S-1 with cisplatin)

FL/Tax DRUG

\<Every q 3 weeks\> 1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours 2. Day1 : Leucovorin 20mg/m2 IVF for 1hour 3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Also known as: Paclitaxel with Leucovorin with 5-FU

FL/Tax(Paclitaxel with Leucovorin with 5-FU)

FL/Doc DRUG

\<Every q 3 weeks\> 1. Day1 : Docetaxel 75mg/m2 IVF for 1hour 2. Day1 : Leucovorin 20mg/m2 IVF for 1hour 3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours

Also known as: Docetaxel with Leucovorin with 5-FU

FL/Doc(Decetaxel with Leucovorin with 5-FU)

FOLFOX DRUG

\<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours

Also known as: Oxaliplatin with Leucovorin with 5-FU

FOLFOX(Oxaliplatin with Leucovorin with 5-FU)

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed adenocarcinoma of the stomach
• Unresectable metastatic disease or recurred AGC
• Age ≥ 20 years old
• Eastern Cooperative Oncology Group performance status 0-2
• Estimated life expectancy \> 12weeks
• Patients with pre-treatment(radiotherapy, chemotherapy) is not carried out. (However, adjuvant chemotherapy using one kind of medication is allowed. It must passed more than 6 months since end of the treatment.) Conventional radiation therapy should be performed before more than 2 weeks. And it is not allowed radiation therapy on primary tumor, measurable lesions, and abdominal
• According to RECIST ver.1.1, using imaging techniques (CT or MRI), measurement possible disease or not measurable, but assessable disease
• Screening laboratory values within the following limits : Hemoglobin ≥ 9 g/dL, Absolute neutrophil count ≥ 1.5 x 10³/L, Platelet count ≥ 75 x 10³/L, Serum creatinine ≤ 1.5 x UNL, Creatinine clearance ≥ 50 mL/min, AST/ALT ≤ 5.0 x UNL
• The patient or protector have to sign a consent form. And he should be able to understand the right to withdraw consent without disadvantage.

You may not qualify if:

• Prior chemotherapy (however, previous (neo-)adjuvant chemotherapy allowed if finished at least 6month ago except S-1, Paclitaxel, Docetaxel, Oxaliplatin . Allowed 5-FU, Cisplatin if finished 6month ago)
• Patients with oral intake is impossible or with malabsorption syndrome
• Patients with medically uncontrolled severe complications or infection
• Patients who have central nervous system disorders, mental disorders, or evidence of CNS metastases
• Patient with diagnosed active overlapping cancer within the past 5years except adequately treated carcinoma insitu of the cervix, basal or squamous cell carcinoma of skin
• The possibility(will) of pregnancy , or pregnant and lactating women
• Patients with clinically significant heart disease
• Progression of gastric lesions is not possible to evaluate
• During clinical trials, patient receiving of systemic chemotherapy or other clinical trials drugs or radiotherapy (However, it is possible that palliative radiotherapy treatment for pain relief on primary lesion after more than 2 weeks)
• Peripheral neuropathy of Grade 2 or greater.
• Patients who taking drugs to change of pharmacological activity of S-1 medicine(Warfarin, phenytoin, allopurinol etc.). Except regular treatment of corticosteroids(or equivalent drugs). However, it is allowed the purposes for pre-treatment of study drugs and the control of nausea and vomiting. (However, it is allowed the treatment for acute allergic reactions, or the treatment with low doses (methylprednisolone 20mg or less, or the equivalent drug) from about 6 months)
• Other cases
• Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.
• Psychological condition or dementia that would not permit the subject to complete the study or sign informed consent
• Patients with dropout sure in clinical trials or cannot be regular follow-up following reasons. For example, psychological, social, family, geographic reasons or a difficult condition of compliance with clinical trial and proper follow up.

Sponsors & Collaborators

• Yonsei University: lead

Study Sites (1)

Severance Hospital

Seoul, 120-752, South Korea

Location

MeSH Terms

Conditions

Recurrence; Stomach Neoplasms

Interventions

titanium silicide; Cisplatin; Paclitaxel; Leucovorin; Fluorouracil; Docetaxel; Folfox protocol; Oxaliplatin

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Coenzymes; Enzymes and Coenzymes; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Coordination Complexes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 24, 2011
• First Posted: January 25, 2011
• Study Start: March 9, 2010
• Primary Completion: July 25, 2016
• Study Completion: July 25, 2016
• Last Updated: January 29, 2019

Record last verified: 2019-01

Locations

KR (1)